Logo image of FGEN

FIBROGEN INC (FGEN) Stock Fundamental Analysis

NASDAQ:FGEN - Nasdaq - US31572Q8087 - Common Stock - Currency: USD

0.3285  0 (-1.05%)

Premarket: 0.32 -0.01 (-2.59%)

Fundamental Rating

2

FGEN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. FGEN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, FGEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year FGEN has reported negative net income.
In the past year FGEN has reported a negative cash flow from operations.
FGEN had negative earnings in each of the past 5 years.
FGEN had negative operating cash flow in 4 of the past 5 years.
FGEN Yearly Net Income VS EBIT VS OCF VS FCFFGEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

FGEN has a Return On Assets of -6.06%. This is amongst the best in the industry. FGEN outperforms 87.34% of its industry peers.
Industry RankSector Rank
ROA -6.06%
ROE N/A
ROIC N/A
ROA(3y)-45.81%
ROA(5y)-39.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FGEN Yearly ROA, ROE, ROICFGEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

FGEN has a Gross Margin of 109.67%. This is amongst the best in the industry. FGEN outperforms 99.64% of its industry peers.
FGEN's Gross Margin has declined in the last couple of years.
FGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 109.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.51%
GM growth 5Y-13.76%
FGEN Yearly Profit, Operating, Gross MarginsFGEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

1

2. Health

2.1 Basic Checks

FGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FGEN has been increased compared to 1 year ago.
Compared to 5 years ago, FGEN has more shares outstanding
FGEN has a worse debt/assets ratio than last year.
FGEN Yearly Shares OutstandingFGEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
FGEN Yearly Total Debt VS Total AssetsFGEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -17.04, we must say that FGEN is in the distress zone and has some risk of bankruptcy.
FGEN's Altman-Z score of -17.04 is on the low side compared to the rest of the industry. FGEN is outperformed by 83.42% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.04
ROIC/WACCN/A
WACC14.75%
FGEN Yearly LT Debt VS Equity VS FCFFGEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 2.02 indicates that FGEN has no problem at all paying its short term obligations.
The Current ratio of FGEN (2.02) is worse than 75.22% of its industry peers.
FGEN has a Quick Ratio of 1.98. This is a normal value and indicates that FGEN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of FGEN (1.98) is worse than 74.51% of its industry peers.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.98
FGEN Yearly Current Assets VS Current LiabilitesFGEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 95.69% over the past year.
Looking at the last year, FGEN shows a very negative growth in Revenue. The Revenue has decreased by -38.58% in the last year.
Measured over the past years, FGEN shows a very negative growth in Revenue. The Revenue has been decreasing by -35.07% on average per year.
EPS 1Y (TTM)95.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.15%
Revenue 1Y (TTM)-38.58%
Revenue growth 3Y-49.88%
Revenue growth 5Y-35.07%
Sales Q2Q%-95.1%

3.2 Future

FGEN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.41% yearly.
The Revenue is expected to grow by 9.58% on average over the next years. This is quite good.
EPS Next Y-8.37%
EPS Next 2Y-23.69%
EPS Next 3Y-7.22%
EPS Next 5Y20.41%
Revenue Next Year-45.65%
Revenue Next 2Y-22.98%
Revenue Next 3Y-11.96%
Revenue Next 5Y9.58%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
FGEN Yearly Revenue VS EstimatesFGEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
FGEN Yearly EPS VS EstimatesFGEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FGEN Price Earnings VS Forward Price EarningsFGEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FGEN Per share dataFGEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

FGEN's earnings are expected to decrease with -7.22% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.69%
EPS Next 3Y-7.22%

More info and screens

0

5. Dividend

5.1 Amount

FGEN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FIBROGEN INC

NASDAQ:FGEN (5/22/2025, 8:00:34 PM)

Premarket: 0.32 -0.01 (-2.59%)

0.3285

0 (-1.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners36.98%
Inst Owner Change-8.49%
Ins Owners0.63%
Ins Owner Change0.97%
Market Cap33.19M
Analysts80
Price Target10.2 (3005.02%)
Short Float %3.78%
Short Ratio3.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)185.57%
Min EPS beat(2)145.1%
Max EPS beat(2)226.05%
EPS beat(4)4
Avg EPS beat(4)116.87%
Min EPS beat(4)45.36%
Max EPS beat(4)226.05%
EPS beat(8)6
Avg EPS beat(8)57.32%
EPS beat(12)8
Avg EPS beat(12)39.98%
EPS beat(16)10
Avg EPS beat(16)569.61%
Revenue beat(2)1
Avg Revenue beat(2)2.98%
Min Revenue beat(2)-92.44%
Max Revenue beat(2)98.39%
Revenue beat(4)3
Avg Revenue beat(4)19.97%
Min Revenue beat(4)-92.44%
Max Revenue beat(4)98.39%
Revenue beat(8)6
Avg Revenue beat(8)16.2%
Revenue beat(12)8
Avg Revenue beat(12)9.58%
Revenue beat(16)10
Avg Revenue beat(16)6.09%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)59.09%
EPS NQ rev (3m)10%
EPS NY rev (1m)27.66%
EPS NY rev (3m)-12.09%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-41.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.32
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.75
OCFYN/A
SpS1.02
BVpS-2.15
TBVpS-2.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 109.67%
FCFM N/A
ROA(3y)-45.81%
ROA(5y)-39.56%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.51%
GM growth 5Y-13.76%
F-Score4
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.51%
Cap/Sales 0.25%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 1.98
Altman-Z -17.04
F-Score4
WACC14.75%
ROIC/WACCN/A
Cap/Depr(3y)133.57%
Cap/Depr(5y)124.53%
Cap/Sales(3y)11.27%
Cap/Sales(5y)9.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%115.15%
EPS Next Y-8.37%
EPS Next 2Y-23.69%
EPS Next 3Y-7.22%
EPS Next 5Y20.41%
Revenue 1Y (TTM)-38.58%
Revenue growth 3Y-49.88%
Revenue growth 5Y-35.07%
Sales Q2Q%-95.1%
Revenue Next Year-45.65%
Revenue Next 2Y-22.98%
Revenue Next 3Y-11.96%
Revenue Next 5Y9.58%
EBIT growth 1Y48.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.29%
EBIT Next 3Y1.87%
EBIT Next 5Y1.99%
FCF growth 1Y68.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y68.21%
OCF growth 3YN/A
OCF growth 5YN/A